Stereotaxis Printed a Record Quarter and Got Priced for Parts
A 20% revenue beat, a stock cut in half in 90 days, and a convertible note whose second half only unlocks if the one thing management has failed to deliver finally gets delivered.
STXS · Earnings Call · 2026-11-10
When the Financing Document Is the Strategy
Stereotaxis reported $8.9 million of third-quarter revenue on November 10 — up 20% year over year, up 16% sequentially, and roughly tied with the best quarters in a ten-year series that otherwise drifts gently sideways. System revenue of $3.0 million rose 60% on partial recognition of the first US GenesisX sale, the first Genesis in China, and a full quarter of Synchrony digital-cockpit sales. By the standards of a company that has spent fifteen years not growing, this was a very good quarter. The stock is down 50% in 90 days — from $1.80 on July 8 to roughly $0.90, a market cap of about $90 million. The reason sits in the same press release: a convertible note of $12 million funded upfront, with an optional additional $12 million available "following certain regulatory milestones." “This structure reflects our belief that the financing bridges us to profitability within the next year.” — David Leo Fischel, CEO · 2026-11-10 Read that carefully. The second tranche is not a shelf; it is a bet the company is asking investors to make on a regulatory decision that has not yet happened, and that decision is what addresses the catheter shortage strangling the recurring-revenue business. The equity has been re-underwritten around a filing. Pro forma cash is $16 million, with total availability of $28 million, against a $6.5 million quarterly burn and $4 million of cash at September 30.The Bottleneck Has a Name
The strategy is a classic razor/razor-blade: install robots, sell the robotic catheters each procedure consumes. The second half broke. Contract manufacturer Osypka could not scale MAGIC production, and the CEO did not sugarcoat it.This is where the story gets interesting, because it is a milestone that moved while nobody was watching. On the May call, David Fischel stated the target plainly: “we are working towards 500 catheters per month by the end of this year” — David Leo Fischel, Chairman and CEO · 2026-05-12. By August, re-asked directly, the answer was more hedged. On Tuesday, asked again about "that 500 catheters per month watermark," he did not reaffirm the date at all — the shortage is now framed as resolving in early 2027, contingent on regulatory approvals for a redundant, in-house supply line. That is the honest answer and also a slip of roughly two quarters on the single variable that drives the recurring revenue model. The company entered Q4 with $1.9 million of unconvertible disposable orders. Management believes “probably about half of that, if not a little bit more than half of that will be resolved in this quarter” — David Leo Fischel, CEO · 2026-11-10, and expects a high watermark for recurring revenue anyway — because Europe has been pivoted to two alternative catheters the company exclusively distributes, freeing scarce MAGIC units for the US. That is a resourceful dodge, and it is also an admission that the supply chain is now a geographic allocation problem. It is a company-specific wound, not a sector one; the kind of supply chain constraint other industrial names announce with far less drama and far less consequence.They have grossly underperformed their own expectations for the year in the ramp, and we have essentially seen... we saw some ramp up early in the year, and then have essentially. You know, there were little kind of green shoots of potential improvement, where we thought that there was improvement, and then kind of they had supply challenges again.
What Actually Improved: The Room Itself
The genuine positive of the quarter was regulatory and architectural. For its entire history, Stereotaxis robots required a magnetically shielded, modified X-ray and a construction project. GenesisX breaks that. “A clear requirement for the broad adoption of GenesisX by hospital customers is ensuring it can be used interoperably with various standard X-rays.” — David Leo Fischel, CEO · 2026-11-10 August brought FDA clearance for exactly that label; late October brought a co-marketing and compatibility collaboration with Canon, whose X-ray is particularly strong in pediatrics — and the first US GenesisX installs this month alongside it. That is the structural transformation the market has been waiting on for years, and it is now starting to show up as commercial impact in the system line. The pipelines are now countable in dozens rather than units: a couple dozen GenesisX opportunities, a few dozen actionable Synchrony systems within a year, and roughly fifty in the Synchrony queue. Synchrony alone is guided to about $1 million a quarter near-term, with "a couple of million" quarters plausible. Robocath's R Star system — a mechanical robot with human-like fingers manipulating five catheters in tandem — presented first-in-human coronary data at TCT and is moving toward design freeze. Management calls these regulatory milestones rather than revenue events, which is the right register.The Thing They Stopped Saying
Stereotaxis's own keyword history is unusually revealing. ASC setting — ambulatory surgery centers — was the single highest-momentum theme in the second-quarter call, with the CEO saying he hoped one of that year's GenesisX installations would land in an ASC. It is absent this quarter, and its momentum had already flipped negative. Likewise the "five GenesisX programs" target from March has dissolved into a vaguer "pipeline." When a small-cap stops quantifying a target it has spent two quarters quantifying, that is information. What replaced it is more defensible: congenital heart disease and the adjacent complex niches — roughly 1% of a $16 billion-plus ablation market for pediatrics, maybe 10% for VT and PVC — genuinely an underserved niche where MAGIC carries the only FDA approval for congenital patients. Sizing a beachhead honestly at 1–3% of a huge market is more credible than promising a new care setting.The Arithmetic of the Bet
The fundamentals show why the equity is so levered to execution. Latest filed figures (Q1, before the last two quarters of revenue growth) show revenue of $6 million, down 16% year over year and an operating margin of −95%. Free cash flow ran at −$6 million in the quarter. Yet the shares still carry a 5.7x trailing revenue multiple, and receivables at 84% of revenue. R&D intensity stays around a third of sales via R&D as a share of revenue — a company spending like a platform, earning like a startup. Two quarters of reconciliation matter here. In August, the breakeven language was specific:. On Tuesday the same idea became "a clear pathway to profitability next year," with adjusted operating expenses guided to roughly $8 million a quarter from $9.1 million. Note also that the install guidance softened from August's “I hope we can get towards 5, but we'll definitely have 2” — David Fischel, Chief Executive Officer · 2026-08-11 to a single confirmed US install this month plus Europe and "visibility" to one more in early 2027. The bull case is coherent and, for the first time, mechanically plausible: an installable robot removes the construction barrier, a Canon partnership removes the X-ray objection, and a second supply source removes the catheter ceiling. The financing is priced at a 30% premium to the recent share price with interest due at maturity in three years — investors who could see the files lent on it. But every one of those three unlocks is still ahead, and the equity has already been marked down 50% while management waits. The market is not disputing the strategy. It is disputing the timing, and it is disputing who funds it if the next milestone slips the way the last one did.we get to breakeven in the first half of next year and cash flow profitability kind of at that point